Literature DB >> 762665

Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats.

J L Cangiano, C Rodríguez-Sargent, M Martínez-Maldonado.   

Abstract

The effects of pretreatment with hydralazine and alpha-methyldopa were assessed in rats made hypertensive by ligation of the left renal artery (LRA). Systolic blood pressure and peripheral renin activity (PRA) were measured 7 and 1 day before LRA and 2, 7 and 28 days after LRA. Systolic blood pressure increased 2 days after LRA in control and alpha-methyldopa-treated rats but not in the hydralazine-treated rats. Peripheral renin activity levels did not correlate with changes in systolic blood pressure. Peripheral renin activity first increased 7 days after LRA but decreased 28 days after LRA despite persistent hypertension in controls and alpha-methyldopa-treated rats. It is concluded that factors other than renin are involved in the initial and maintenance phases of this experimental model. In addition, hydralazine protects the rat with LRA from developing hypertension.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 762665

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


  6 in total

1.  Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.

Authors:  A Hilditch; H M Prior; G M Drew
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

2.  Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.

Authors:  D P Brooks; T A Fredrickson; J Weinstock; R R Ruffolo; R M Edwards; M Gellai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

3.  Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Authors:  W Wienen; N Hauel; J C Van Meel; B Narr; U Ries; M Entzeroth
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

4.  Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.

Authors:  A Hilditch; A A Hunt; C J Gardner; D J Twissell; J Polley; A Travers; G M Drew; D Middlemiss; B C Ross; M J Robertson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

5.  Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.

Authors:  R Cirillo; A R Renzetti; P Cucchi; M Guelfi; A Salimbeni; S Caliari; A Castellucci; S Evangelista; A Subissi; A Giachetti
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

6.  Strength Training Reduces Cardiac and Renal Oxidative Stress in Rats with Renovascular Hypertension.

Authors:  Rodrigo Miguel-Dos-Santos; Jucilene Freitas Dos Santos; Fabricio Nunes Macedo; Anderson Carlos Marçal; Valter J Santana Filho; Rogerio Brandão Wichi; Sandra Lauton-Santos
Journal:  Arq Bras Cardiol       Date:  2021-01       Impact factor: 2.000
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.